In other words, roughly half as much 4SP65 (2.23- to 1.58-fold lower concentrations) was required to achieve equivalent responses at each dose-response metric in TP53-mutant cancer cell lines compared to TP53 wild-type cell lines. The gene discussed is TP53; the disease is cancer.